Dudnyk President Award Finalist
Frank X. Powers, President of Dudnyk advertising, has been named as a healthcare/biotech finalist for the 2013 Philadelphia Circle of Excellence award as announced by Philadelphia SmartCEO magazine. The magazine reports that Powers is one of the region’s most respected, innovative and forward-thinking company presidents or CEOs.
Dudnyk is a full-service healthcare and medical advertising agency that supports biotech, biopharma and medical device companies. The company specializes in developing branded and unbranded multi-channel communications through scientific and creative strategies. In 2012, it was the winner of Med Ad News’ Best Professional Campaign, and in 2011, PM360 named it the Advertising Agency of the Year.
“My success in leading Dudnyk is due in large part to the talented people who call Dudnyk ‘home,’ ” Powers says, “and to our amazing clients who encourage us to be true partners in their accomplishments.”
Precision Names Richard O’Connor CFO
Precision Health Media, known as the leading source for advertisers in reaching digital health audiences, recently named Richard O’Connor as the first Chief Financial Officer of the company. In addition to O’Connor, Peter Fontana has been named VP of Advertising Sales, and Andy Chapman as a member of the Board of Advisors.
O’Connor, previously co-founder and CFO of Prime Visibility Media Group, led the company to a $36 million acquisition by Blinkx. He also held positions at Universal Domestic Television and Warner Bros.
CEO of Precision Health Media, Bill Jennings says, “We’re well poised to explore new areas of growth as we enter 2014. Rich brings us a wealth of financial expertise as we consider new funding options.” The New York-based company is backed by Metamorphic Ventures, Cava Capital, and several other investors linked to Forbes, Flycast and Collective, to name a few.
3-V Biosciences, Inc., a private pharmaceutical company specializing in therapeutics, appointed William McCulloch as Chief Medical Officer. Dr. McCulloch has nearly 30 years of experience in senior research and development for 3-V. He will be responsible for clinical, medical affairs and regulatory functions, and for overseeing strategy for the advancement of 3-V’s pipeline of proprietary therapeutic candidates.
Alliqua, Inc., a biopharmaceutical company focused on the development, manufacturing, and distribution of proprietary transdermal wound care and drug delivery technologies, appointed Perry A. Karsen as the ninth member of the Board of Directors. Karsen is currently CEO of Celgene Cellular Therapeutics and specializes in wound care space development.
Philip Andrew Gioia has been appointed President of the North America and Global API business departments of Glenmark Pharmaceuticals. Gioia will be reporting to the Chairman and Managing Director in his new position. Glenmark is a research-driven, global, integrated pharmaceutical company headquartered in Mumbai, India. Gioia will be based in Mahwah, New Jersey.
Lorus Therapeutics, Inc. appointed Avanish Vellanki as Chief Business Officer, and Gregory K. Chow as Chief Financial Officer. Vellanki will manage global business development, licensing and corporate strategy. Chow will be responsible for corporate finance and accounting functions. Lorus Therapeutics is a biopharmaceutical company that targets essential apoptosis pathways to deliver transformational cancer drugs.
OXiGENE, a clinical stage biopharmaceutical company specializing in cancer treatment devices, appointed Frederick W. Driscoll to its Board of Directors. With more than 30 years of experience in the biotechnology and medical device industries, Driscoll will serve as Chairman of the Board of Directors.
Regado Biosciences, Inc., a biopharmaceutical company focused on the late-stage clinical development of first-in-class, actively controllable antithrombotic drug system, REG1, today announced that Deepak L. Bhatt, MD, MPH, FACC, FAHA, has joined the company’s Medical Advisory Board. Regado will benefit from Dr. Bhatt’s expertise in cardiovascular intervention and years of experience leading international cardiovascular clinical trials.
John G. Cox has been elected to the Board of Directors of Repligen Corporation. Cox has over 20 years of experience in biopharmaceutical manufacturing with Biogen Idec, Inc., and supported the commercial launches of a variety of major biologic drugs. Repligen Corporation focuses on the development, production and commercialization of high-value consumable products used in the process of manufacturing biological drugs.
Rx EDGE Pharmacy Networks
The pharmacy-based marketing services company, Rx EDGE Pharmacy Networks, has announced the promotions of Rob Blazek to Vice President, Network Strategies and Tracie Young to Vice President, Finance. Blazek, a registered pharmacist, will be responsible for optimizing partnerships with the key pharmacy retailers who make up the company’s primary marketing channel. Young was formerly Senior Director of Finance and will take on an expanded leadership role in the finance and human resources departments.
Savara Pharmaceuticals, a specialty pharma company, recently announced Dr. Joseph S. McCracken and Yuri Pikover to its Board of Directors. Dr. McCracken has more than 25 years of experience in technical business and market development with biotechnology and pharma companies. Pikover is a Managing Director of 37 Technology Ventures, a boutique venture fund that focuses on the growth of startups.
Scioderm, Inc. appointed John Crowley and William Aliski as the newest members of its Board of Directors. Crowley currently serves as CEO of Amicus Therapeutics, and possesses significant knowledge in rare and orphan diseases as well as public market experience. Aliski has over 25 years of senior executive orphan drug commercial management experience, including time spent with FoldRx Pharmaceuticals. Scioderm is a private pharmaceutical company focused on treatments for diseases with high unmet needs.